Literature DB >> 2040531

Evaluation of circulating tumor necrosis factor-alpha in patients with gynecological malignancies.

P De Jaco1, B Asselain, C Orlandi, W H Fridman, J L Teillaud.   

Abstract

TNF-alpha levels in sera from patients with gynecological cancers were evaluated by ELISA and compared with those of patients with benign ovarian cysts or of anonymous healthy donors. Patients with cervical and endometrial carcinoma and with benign ovarian cysts showed levels of TNF-alpha similar to those of healthy donors. In contrast, significantly increased levels of TNF-alpha were found in patients with ovarian carcinoma, regardless of the stage of disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040531     DOI: 10.1002/ijc.2910480311

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.

Authors:  A G Bais; I Beckmann; J Lindemans; P C Ewing; C J L M Meijer; P J F Snijders; T J M Helmerhorst
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

2.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Authors:  Anne M Noonan; Kristen P Bunch; Jin-Qiu Chen; Michelle A Herrmann; Jung-Min Lee; Elise C Kohn; Ciara C O'Sullivan; Elizabeth Jordan; Nicole Houston; Naoko Takebe; Robert J Kinders; Liang Cao; Cody J Peer; W Douglas Figg; Christina M Annunziata
Journal:  Cancer       Date:  2015-11-13       Impact factor: 6.860

3.  Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor.

Authors:  S T Malik; N East; D Boraschi; F R Balkwill
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.